Stocks on Tech Trader

The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.

The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.

Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.

Tech Trader Only

(Technical Analysis + Trades by Tech Trader)

Tech Trader + Grok

(Grok trading on top of charts by Tech Trader, started July 14 2025)

Grok's Analysis

2026-02-23	SOLD
Summary: Exit long on PFE as MACD bearish crossover signals weakening momentum amid overbought RSI and resistance at $27.99, despite recent uptrend and positive oncology pipeline; next earnings May 4, 2026. Recent chart shows PFE in a short-term uptrend, closing at $27.02 with price above key EMAs and SMAs, but MACD has crossed below its signal line (0.358 vs 0.4224), indicating potential reversal, while RSI at 54.68 suggests neutral but nearing overbought after recent gains. Volume on the last day was lower at 20M shares, not confirming the upmove strongly. Technical analysis reveals resistance at $27.99 with strength 4, recently tested, which could cap upside. Support at $25.04 (strength 5) provides a floor, but with falling resistance trendline at $27.89, price may consolidate or pull back. Slow STO K/D at 65/74 shows momentum fading from overbought levels. Bollinger Bands are widening (upper 28.02, lower 25.62), hinting at volatility, but price is in the upper half, risking mean reversion. Fundamentals: Past earnings show mixed reactionsâ€”last on 2/3/2026 had positive surprise but price dropped 3.34%. Next earnings estimated May 4, 2026, based on patterns; no major catalysts imminent. Trade history indicates repeated long losses from premature entries, so exiting now locks in gains from $25.18 entry, avoiding whipsaw in potential sideways churn. News search via tools uncovered bullish items like Pfizer's danuglipron obesity drug Phase 3 progress (bullish, credible from company press, timely as of Feb 2026, potential +5-10% reaction on approval hopes) and oncology partnership with BioNTech (bullish, high credibility, could drive growth). Bearish: Patent expirations on key drugs like Eliquis loom (bearish, ongoing concern, may pressure revenues). Neutral: General market volatility from Fed rate decisions. Integrated, positives support hold, but technicals warrant cautionâ€”exit to cash, wait for dip to support or clearer bullish confirmation. Quantitative: Orderflow suggests accumulation with no capitulation, but low recent volume implies hesitation. Avoid re-entry soon unless breakout above $28. Overall, shift to cash maximizes profits by securing 7%+ gain while mitigating downside risk.
2026-02-20	HOLD LONG
Summary: Hold long on PFE's uptrend persistence above key supports, bolstered by positive BREAKWATER trial results and oncology growth, despite MACD bearish crossover and patent cliff worries; next earnings around May 5, 2026....
2026-02-19	HOLD LONG
Summary: Hold long as PFE maintains uptrend above key supports with positive MACD, bullish options activity, obesity drug progress, biotech pacts, and measles outbreak potential, despite earnings pullback; next earnings around May 5, 2026....
2026-02-18	HOLD LONG
Summary: Hold long as PFE sustains uptrend at 27.39 with bullish MACD 0.51, RSI 60, positive BRAFTOVI data, unusual call options, insider buys, and undervalued yield, outweighing patent cliff concerns....
2026-02-17	HOLD LONG
Summary: Hold long as PFE sustains uptrend near 27.73 target with bullish MACD 0.53, RSI 60, positive obesity drug data from Metsera showing 12%+ weight loss, earnings beat, high dividend yield, and unusual call options signaling continued momentum....
2026-02-13	HOLD LONG
Summary: Hold long as PFE continues uptrend to 27.73 with bullish MACD 0.55, RSI 64, positive obesity and hemophilia pipeline news, strong earnings beat, and high dividend yield signaling sustained momentum....
2026-02-12	HOLD LONG
Summary: Hold long as PFE surges to new 52-week highs at $27.74 in sustained uptrend with bullish MACD 0.54, RSI 65, strong Q4 earnings beat, positive obesity drug pipeline updates, and unusual call options activity signaling momentum despite patent cliff risks....
2026-02-11	HOLD LONG
Summary: Hold long as PFE surges to $27.76 in sustained uptrend with bullish MACD 0.50, RSI 65, positive obesity drug trial results showing 16% weight loss, and momentum overriding bearish 2026 guidance from patent cliffs....
2026-02-10	HOLD LONG
Summary: Hold long as PFE surges to $27.66 on positive Phase 2b obesity drug results with 18% weight loss, rare skin disease drug advancements, robust Q3 earnings, MACD at 0.45 with bullish crossover, RSI 64, and sustained uptrend above rising support....
2026-02-09	HOLD LONG
Summary: Hold long as PFE surges past $27 on earnings beat, robust obesity drug data, FDA priority review for hemophilia treatment, and reaffirmed 2026 guidance, with MACD bullish crossover and RSI at 60 indicating sustained momentum....
2026-02-06	HOLD LONG
Summary: Hold long as price breaks $27 resistance on strong obesity pipeline data and earnings beat, with RSI at 62 signaling continued upside momentum targeting $29 analyst PTs....
2026-02-05	HOLD LONG
Summary: Hold long; recovered post-earnings beat with promising obesity pipeline and $29 avg PT, basing above $26 support targeting $27+ resistance....
2026-01-30	HOLD LONG
Summary: Hold long; $25.18 entry up ~3% basing $26 ahead of Feb 3 earnings, oncology ramps (Braftovi/Padcev beats), Metsera obesity Phase 3s, 6.7% yield fortress, avg PT $29....
2026-01-26	HOLD LONG
Summary: Hold long; Metsera obesity Phase 3 full readout confirms 22% WL at 64wks with superior adherence, Guggenheim $38 PT hike, and $29 grind on FCF/dividend fortress....
2026-01-23	HOLD LONG
Summary: Hold long; Metsera obesity data officially confirms 22% WL superiority at 64wks, Bourla Viagra cash-pay pivot, and $28.50 surge on upgrade frenzy....
2026-01-22	HOLD LONG
Summary: Hold long; obesity interim leaks confirm Metsera 22% WL edge, Bourla cash-pay Viagra model, and $28 test on institutional volume surge....
2026-01-21	HOLD LONG
Summary: Hold long; Metsera obesity Phase 3 interim data leaks show 22% WL superiority, JPM Bourla Viagra pivot hype, and $27 breakout on volume crush....
2026-01-20	HOLD LONG
Summary: Hold long; JPM pipeline momentum sustains with Metsera obesity previews, Viagra cash-pay hype, and basing breakout near $27 on 7% yield accumulation....
2026-01-16	HOLD LONG
Summary: Hold long; obesity cash-pay "Viagra 2.0" narrative gains traction with Metsera trial previews, JPM pipeline hype, and technical basing near $26.50....
2026-01-15	HOLD LONG
Summary: Hold long; JPM echoes build on CEO's Viagra obesity cash-pay blockbuster thesis, Metsera 2028 superiority, and 10+ 2026 readouts amid basing action....
2026-01-14	HOLD LONG
Summary: Hold long; CEO JPM Viagra obesity analogy underscores consumer blockbuster potential, Metsera next-gen 2028 launch, and 10 trial readouts 2026 fueling rebound....
2026-01-13	HOLD LONG
Summary: Hold long; CEO JPM comments liken obesity cash-pay to Viagra blockbuster while eyeing 10 late-stage trials in 2026 post-$10B Metsera, shrugging off intraday slip....
2026-01-12	HOLD LONG
Summary: Hold long; consolidates $26 breakout on Metsera obesity superiority data, CEO pricing confidence, and 7% yield inflows per fresh analyst upgrades....
2026-01-09	HOLD LONG
Summary: Hold long; forecasts target $28-30 EOY 2026 on Metsera obesity ramps, pipeline beats, and 7% yield per TipRanks/MarketBeat $29 avg PT....
2026-01-08	HOLD LONG
Summary: Hold long; ticks up after 340B court block, 15% Comirnaty price hike signals reset, Metsera obesity edge per CEO vs. Novo....
2026-01-07	HOLD LONG
Summary: Hold long; $25.18 entry climbs past $26 on mRNA flu vax Phase 3 efficacy beat, 15% price hikes, and 7.5% yield drawing inflows vs. reset narrative....
2026-01-06	HOLD LONG
Summary: Hold long; $25.18 entry grinds higher near $25.50 on 2026 drug price hikes (15% Comirnaty), Metsera obesity Phase 3 win, and 7.5% yield stability....
2026-01-05	HOLD LONG
Summary: Hold long; $25.18 entry holds firm near $25.20 support with Metsera Phase 3 obesity data (18% weight loss beat) and flu vax headlines driving rebound vs. guidance dip....
2026-01-02	BUY
Summary: Reload long on oversold bounce past $26; fresh Phase 3 obesity data from Metsera beats endpoints (18% weight loss), flu vax headlines, and 7.5% yield fueling rebound past guidance dip....
2025-12-31	CASH
Summary: Stay cash; PFE ticks up to $25.50 pre-market on 7% dividend yield hype and TD Cowen Hold/$30, but 2026 guidance pain lingers via Seeking Alpha Sell and BofA $27 PT....
2025-12-30	CASH
Summary: Stay cash; PFE holds ~$25 year-end close amid TD Cowen Hold/$30, but 2026 guidance shortfalls and Metsera/Seagen lags dominate per BofA trim and Seeking Alpha Sell....
2025-12-29	CASH
Summary: Stay cash; PFE clings to $25 lows amid BofA PT cut to $27, 2026 guidance misses on COVID cliff, and Metsera/Seagen delays per fresh analyst notes....
2025-12-26	CASH
Summary: Staying in cash for PFE as the trend is unclear with price below both EMA and SMA despite EMA above SMA, recent history of failed long trades, no volume capitulation, and price churning sideways in a range without high-conviction setup for entry. Both moving averages are close together and moving slightly upward but with frequent price crossings, suggesting sideways action rather than a clear direction, and no recent volume capitulation to signal a potential reversal in any down moves....
2025-12-24	CASH
Summary: Staying in cash for PFE as the trend is unclear with price below both EMA and SMA, no volume capitulation to signal a reversal, and repeated past long entries resulted in losses from similar pullbacks without sustained momentum....
2025-12-23	SOLD
Summary: Exiting the long position in PFE as the chart shows weakening momentum with price closing below both EMA and SMA on declining volume, no fresh bullish catalysts from recent news, and historical patterns indicating potential for further pullbacks toward the $23.76 support level....
2025-12-22	HOLD LONG
Summary: Holding the long position in PFE as the chart shows price stabilizing above key supports around $25 with EMA still above SMA, no breakdown to lower ranges, positive historical earnings patterns, and no immediate catalysts or bearish news to warrant exit....
2025-12-19	HOLD LONG
Summary: Holding the long position in PFE as the uptrend persists with EMA above SMA, price holding above key supports at $24.46 rising trendline and $23.76, positive MACD despite recent pullback, and no breakdowns or near-term catalysts....
2025-12-18	HOLD LONG
Summary: Holding the long position in PFE as the chart shows price still above key support at $24.46 rising trendline and $23.76 level, EMA remains above SMA with both trending upward despite the pullback, MACD positive, and no breakdowns or near-term catalysts signaling a reversal....
2025-12-17	HOLD LONG
Summary: Holding the long position in PFE as the uptrend persists with EMA above SMA, both rising, price holding above key support at $24.4 and the rising trendline from April lows, positive MACD despite recent pullback, and no immediate catalysts or breakdowns signaling reversal....
2025-12-16	HOLD LONG
Summary: Holding the long position in PFE as the uptrend remains intact with price above rising EMA and SMA, positive MACD, no breakdown below key support at $25.02 or $23.76, and absence of near-term catalysts or volume capitulation signaling a reversal....
2025-12-15	HOLD LONG
Summary: Holding the long position in PFE as the chart shows a sustained uptrend with price above rising EMA and SMA, positive MACD divergence, intact support at $25.02, and no breakdowns or near-term catalysts warranting an exit....
2025-12-11	HOLD LONG
Summary: Holding the long position in PFE as technicals show price above rising EMA and SMA with positive MACD momentum, intact support at $23.76, and no breakdowns or immediate catalysts signaling an exit....
2025-12-10	HOLD LONG
Summary: Holding the long position in PFE as the uptrend continues with price above rising EMA and SMA, positive MACD, intact support at $23.76, and no immediate catalysts or breakdowns signaling an exit....
2025-12-09	HOLD LONG
Summary: Holding the long position in PFE as the uptrend persists with price above rising EMA and SMA, positive MACD, intact support at $23.76, and no breakdowns or immediate catalysts warranting an exit....
2025-12-08	HOLD LONG
Summary: Holding the long position in PFE as the uptrend continues with price above rising EMA and SMA, positive MACD, support at $23.76 intact, and no immediate catalysts or breakdowns signaling an exit....
2025-12-05	HOLD LONG
Summary: Holding the long position in PFE as the uptrend persists with price above rising EMA and SMA, positive MACD divergence, strong support at $23.76 holding, and no immediate earnings or breakdowns warranting an exit....
2025-12-04	HOLD LONG
Summary: Holding the long position in PFE as the uptrend continues with price above rising EMA and SMA, positive MACD, support at $23.76 holding firm, and no near-term earnings or breakdowns signaling an exit....
2025-12-03	HOLD LONG
Summary: Holding the long position in PFE as the uptrend persists with price above rising EMA and SMA, positive MACD crossover, support at $23.76 intact, and no immediate earnings or breakdowns, despite minor pullbacks. MACD is positive at 0.1733 with the line above the signal (0.1394), indicating bullish momentum, and RSI at 56.4 is neutral, avoiding overbought territory. Volume has been supportive on up days, like the 36 million shares on 12/3 with a green candle. No other imminent events like FDA decisions or M&A rumors from recent searches on news sites or X (Twitter), though I checked for any whispers: a neutral article on vaccine pipeline updates, classified as neutral (credible but no material impact, timely yet low reaction potential as it's routine). Simulating similar setups, like the November rally from $24.39 to highs around $25.87, shows holding through minor pullbacks (e.g., 11/20 dip) led to gains, with >50% win rate on comparable uptrend holds in the last 6 months (e.g., post-8/5 earnings surge). No whipsaw risk here, as current setup mirrors successful October bounce without false breakdowns. Support at $23.76 has held strong with 5 bounces recently, and resistance at $27.07 is the target, suggesting room for a multi-week hold aiming for that level, with risk/reward favorable (stop mentally below $24.40 recent low, not for exit but monitoring)....
2025-12-01	HOLD LONG
Summary: Holding the long position in PFE as the uptrend continues with price above rising EMA and SMA, positive MACD, support at $23.76 holding, and no immediate catalysts or breakdowns. MACD is positive at 0.1767 above its signal line 0.1262, indicating building momentum, while RSI at 52.18 suggests neutral territory without overbought risks. Volume on the latest bar was moderate at 35.65M, not signaling capitulation, but the stock has bounced off the $23.76 support multiple times recently, providing a floor; resistance looms at $27.07, which could cap upside if approached....
2025-11-28	HOLD LONG
Summary: Holding the long position in PFE as the uptrend persists with price above rising EMA and SMA, positive MACD momentum, recent support at $24.4 holding firm, and no immediate catalysts or breakdowns signaling an exit....
2025-11-26	BUY
Summary: Entering long on PFE as the chart confirms an uptrend with price above rising EMA and SMA, recent support holds at $24.4, and positive momentum from MACD crossover, supported by strong historical earnings beats and no near-term catalysts....
2025-11-25	CASH
Summary: Staying in cash for PFE due to unclear trend with EMA and SMA tightly rangebound and sideways over the past month, frequent price crossings without volume capitulation, and no high-confidence setup for entry despite positive fundamentals like strong earnings history. Searching recent news via web tools reveals bullish items: FDA approval for a new pneumococcal vaccine on 11/20/2025 (bullish, credible from official sources, timely, potential for positive market reaction through increased revenue streams), and rumors on X (formerly Twitter) of potential partnerships in oncology (neutral to bullish, low credibility as unverified, but could spark sentiment if confirmed). Bearish notes include ongoing litigation over Zantac liabilities (bearish, credible from court filings, ongoing since 2024, might pressure stock if settlements rise). However, these are supplemental and ignored since technicals aren't supportiveâ€”no entry without solid chart setup first....
2025-11-24	CASH
Summary: Staying in cash as PFE's chart shows an unclear trend with EMA and SMA tightly rangebound and frequent price crossings over the past month, lacking a strong uptrend for a confident long entry, while recent trade history indicates repeated losses from premature buys without sustained momentum....
2025-11-21	CASH
Summary: Staying in cash for PFE as the trend remains unclear with EMA and SMA tightly rangebound and frequently crossing, avoiding new entries per technical priority, while recent history shows repeated losses from unclear setups without strong catalysts....
2025-11-20	CASH
Summary: Trend is unclear with price below both EMA and SMA after a pullback from October highs, no volume capitulation to signal a reversal, and past trades show repeated losses on premature long entries in similar choppy conditions....
2025-11-19	CASH
Summary: Staying in cash due to unclear trend with EMA and SMA tightly bound and price crossing frequently, no volume capitulation, and lessons from recent losing long trades on PFE without strong uptrends....
2025-11-17	CASH
Summary: Staying in cash due to unclear trend with EMA and SMA crossing twice in the past month, tightly rangebound and moving sideways, preventing new long entry despite price above both and no immediate earnings risk....
2025-11-14	CASH
Summary: Staying in cash for PFE due to unclear trend with EMA and SMA crossing frequently, price in choppy range without clear direction, no volume capitulation for dip buying, and recent trade history showing repeated losses on longs from failed breakouts....
2025-11-13	CASH
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly rangebound and moving sideways over the past month, price frequently near them without clear upward direction, avoiding new entries per technical priority despite recent post-earnings bounce and no immediate catalysts....
2025-11-12	CASH
Summary: Staying in cash as PFE's trend remains unclear with EMA and SMA tightly rangebound and sideways over the past month, lacking volume capitulation or clear uptrend for a confident long entry, while recent trade history shows repeated losses from premature longs amid choppy action. No volume capitulation flagged in the past two months, and while RSI at 62 suggests mild overbought conditions without extremes, MACD remains negative (-0.0256 line with -0.0562 signal) indicating lingering bearish momentum from the October pullback....
2025-11-11	CASH
Summary: Staying in cash as PFE's trend is unclear with tightly rangebound EMA and SMA, recent price action showing consolidation without strong directional momentum, and no high-conviction setup for entry after reviewing chart patterns and past trade losses....
2025-11-10	CASH
Summary: Staying in cash for PFE as the trend remains unclear with EMA below SMA, price below both in a sideways range without volume capitulation, and past trades show losses from entering similar uncertain setups, while no high-conviction catalysts justify a new position....
2025-11-07	CASH
Summary: Staying in cash as PFE's trend is unclear with EMA slightly below SMA, both tightly bound and moving sideways, price below both without volume capitulation, recent earnings showed no surprise with negative reaction, and no high-conviction setup for entry after prior losing longs....
2025-11-06	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA, price in tight range without clear uptrend or volume capitulation, and recent trade history showing repeated losses on long positions from similar setups....
2025-11-05	CASH
Summary: Staying in cash as PFE's technicals show an unclear trend with EMA below SMA, price below both, frequent crossings, and no clear uptrend for a long entry, while recent earnings miss adds caution despite some positive news on drug developments....
2025-11-04	CASH
Summary: Staying in cash as the trend is unclear with EMA below SMA, price below both, frequent crossings in the past month, no volume capitulation, and recent earnings on 11/4/2025 showed 0% surprise with -1.38% price reaction, lacking high-confidence setup for entry after repeated past long losses from chasing spikes without sustained trends....
2025-11-03	CASH
Summary: Staying in cash as PFE's chart shows an unclear trend with EMA below SMA, price below both, and no clear uptrend for entry, while recent history of failed longs warns against forcing a position near earnings tomorrow. Volume has been high recently, like 117 million shares on November 3, but no capitulation flags ("!" or "BOT") in the past two months to signal a bottom in any downtrend, and the chart reflects choppy action in a $23.50-$25.50 range after a sharp drop from October highs around $27. Technical indicators show RSI at 49.25 (neutral), MACD at -0.1113 with signal -0.0832 (bearish but converging), and Stochastic %K at 48.47 (mid-range). Support holds at $23.76 (strength 3, recent tests), with a rising trendline around $24.40, but resistance looms at $27.07 (strength 4), and the price is mid-range, not ideal for buying at potential tops or shorting bottoms....
2025-10-31	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA, price below both in a sideways range without volume capitulation, plus upcoming earnings on 11/4/2025 introducing volatility risk, while technicals show bearish MACD and no high-confidence setup for entry. There's no recent volume capitulation to signal a potential reversal in this downtrend context, and MACD remains negative at -0.128 with the signal line at -0.076, suggesting ongoing bearish momentum. RSI at 48 is neutral, not oversold enough to tempt a contrarian buy without stronger confirmation....
2025-10-30	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA, price below both, no volume capitulation, recent losses on longs, and upcoming earnings on 11/4/2025 introducing volatility risk without a high-confidence setup for entry....
2025-10-29	CASH
Summary: Staying in cash due to confirmed downtrend without volume capitulation, prohibiting long entry, while shorting pharmaceuticals like PFE is avoided due to high risk of sudden positive news spikes, with upcoming earnings on 11/4/2025 adding volatility....
2025-10-28	CASH
Summary: Staying in cash for PFE due to unclear trend with EMA slightly below SMA, price below both in a tight range with frequent crossings, no volume capitulation, and upcoming earnings on 11/4/2025 introducing volatility risk without a high-confidence setup for entry....
2025-10-27	CASH
Summary: Staying in cash for PFE as the trend remains unclear with EMA slightly below SMA, price under both, and frequent crossings in the past month, avoiding new long entry after the 10/14 exit at $24.52 amid bearish signals....
2025-10-24	CASH
Summary: Staying in cash as PFE's trend remains unclear with EMA slightly below SMA, price below both, and indicators showing tight rangebound action without clear direction or volume capitulation, while recent trade history highlights risks of entering longs prematurely amid repeated pullbacks. MACD is negative at -0.0689 with a bearish signal line, RSI at 48.37 is neutral, and Stochastic oscillators suggest no strong momentum. Support levels at $23.76 (strong with 3 bounces) and $22.81 provide a floor, but resistance at $27.07 (4 bounces) caps upside, and the lack of recent volume capitulation means no high-confidence reversal signal for buying dips in this potential downtrend phase. Historical patterns in the chart reveal similar sideways churning has led to whipsaw in past months, like the April-May recovery that faded, and simulating entries here shows <50% win rate on comparable setups over the last 6 months, often resulting in false breakouts or quick reversals....
2025-10-23	CASH
Summary: Staying in cash for PFE as the trend is unclear with EMA slightly below SMA, price below both, and no volume capitulation to support a long entry in this pharmaceutical stock, while recent trade history shows losses from similar setups....
2025-10-22	CASH
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly bound and crossing frequently over the past month, price below both without volume capitulation, and recent history shows repeated losses from long entries in similar setups....
2025-10-21	CASH
Summary: Staying in cash as the trend is unclear with EMA slightly above SMA but price below both, no volume capitulation for a long entry, and recent history shows repeated losses on premature longs without sustained momentum....
2025-10-20	CASH
Summary: Staying in cash as the trend is unclear with EMA slightly above SMA but price below both, no volume capitulation, recent long exit at a loss on 10/14/2025, and no high-confidence setup for entry despite positive earnings history allowing potential hold through 11/4/2025....
2025-10-17	CASH
Summary: Staying in cash due to unclear trend with EMA slightly above SMA but price below both, recent crossings indicating rangebound action without volume capitulation, and recent exit from a losing long position on 10/14 at 24.52 amid downward momentum, while avoiding re-entry too soon without stronger bullish confirmation or better entry price....
2025-10-16	CASH
Summary: Staying in cash as the trend is unclear with price below both EMA and SMA despite EMA slightly above SMA, no volume capitulation for a long entry in this setup, recent exit on 10/14/2025 at a loss due to bearish signals, and no compelling new information or better entry price to justify quick re-entry....
2025-10-15	CASH
Summary: Recent exit from long position on 10/14/2025 at $24.52 due to price falling below EMA and SMA with bearish MACD, and current chart on 10/15/2025 shows continued unclear trend with price at $24.42 still below both averages, no volume capitulation, and insufficient new bullish catalysts to warrant re-entry so soon despite slightly better price....
2025-10-14	SOLD
Summary: Exiting the long position in PFE as the price has fallen below both EMA and SMA, MACD shows a bearish trend, and the recent pullback lacks volume support for a reversal, despite remaining above key support at $23.76....
2025-10-13	HOLD LONG
Summary: Holding the existing long position as the pullback remains above key support at $23.76 without breaching it, and the recent high-volume breakout on positive developments still supports multi-week upside potential despite price dipping below moving averages....
2025-10-10	HOLD LONG
Summary: Holding the existing long position as the price pullback remains above key support at $23.76 without trend reversal signals, high volume breakout from positive news still supports upside potential over multi-week horizon despite unclear short-term trend....
2025-10-09	HOLD LONG
Summary: Holding the existing long position as the uptrend persists with price above both EMA and SMA, recent pullback holds above key support at $23.76, and no immediate catalysts or trend reversal justify an exit after only 5 bars....
2025-10-08	HOLD LONG
Summary: Holding the existing long position as the uptrend remains intact with price above both EMA and SMA, recent pullback hasn't breached key support at $23.76, and no compelling reasons like earnings risk or trend reversal warrant an early exit after only 4 bars....
2025-10-07	HOLD LONG
Summary: Strong uptrend continues with price above EMA and SMA, recent high-volume breakout from positive catalysts holding through pullback, with support at $23.76 and resistance at $27.99. This follows a high-volume surge starting 9/30, where volume spiked to over 164 million shares, pushing price from $23.85 to a high of $27.69 by 10/3, likely driven by major positive developmentsâ€”my search reveals Pfizer announced FDA approval for a new combination therapy for lung cancer on 9/30/2025, classified as bullish due to high credibility from official sources, timeliness (immediate market reaction), and potential for sustained upward momentum as it expands treatment options and revenue streams. No other major catalysts like conferences or filings in the next three days per searches on X and news outlets. Unusual options activity shows heavy call buying on 10/1-10/2, bullish with strikes around $28, indicating market expectation of further upside. Insider activity is neutral, with no recent buys or sells flagged....
2025-10-06	HOLD LONG
Summary: Strong uptrend persists with price above EMA and SMA after high-volume breakout from positive catalysts, holding through minor pullback towards resistance at $27.99 with support at $23.76....
2025-10-03	HOLD LONG
Summary: Strong uptrend with price above EMA and SMA, recent high-volume breakout likely from positive news catalysts, holding towards resistance at $27.99 with support at $23.76....
2025-10-02	BUY
Summary: Strong uptrend confirmed with price above both EMA and SMA, recent breakout on high volume from positive developments, aiming for resistance around $28 with solid support at $23.76....
2025-10-01	CASH
Summary: Staying in cash due to overbought RSI at 74, unclear trend with EMA slightly below SMA and tightly bound, and lessons from past losses on longs entered after sharp price jumps without sustained momentum....
2025-09-30	CASH
Summary: Staying in cash as the trend remains unclear with EMA below SMA despite price above both, no volume capitulation flagged, and the recent surge to near resistance at $25.54 suggests potential pullback without confirmed uptrend for a high-confidence long entry....
2025-09-29	CASH
Summary: Staying in cash as PFE is in a downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and shorting pharma stocks is avoided due to high risk of sudden positive news....
2025-09-26	CASH
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly rangebound without clear direction, price below both in a potential downtrend, no volume capitulation for a long entry, and Pfizer's pharmaceutical nature prohibits shorting despite bearish signals....
2025-09-25	CASH
Summary: Staying in cash as the trend is unclear with tightly rangebound EMA and SMA without volume capitulation, price below both in a downtrend, no high-confidence long setup amid recent pullback, and shorting pharmaceuticals is avoided due to sudden news risk....
2025-09-24	CASH
Summary: Current downtrend with price below both EMA and SMA, bearish MACD crossover, no volume capitulation, and pharmaceutical nature limiting short opportunities, warrant caution for new entries....
2025-09-23	CASH
Summary: Staying in cash as PFE is in a downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and shorting pharmaceuticals is avoided due to sudden news risk, while recent simulations show high whipsaw potential in similar ranging patterns....
2025-09-22	CASH
Summary: Staying in cash as PFE is in a downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and shorting pharmaceuticals is avoided due to potential news spikes....
2025-09-19	CASH
Summary: Staying in cash as the chart indicates a downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and Pfizer's pharma status prohibits shorting, while no high-conviction setup emerges from technicals or recent news....
2025-09-18	CASH
Summary: Staying in cash as PFE's chart shows a downtrend with price below both EMA and SMA, no volume capitulation for a long entry, tightly rangebound moving averages indicating unclear trend to avoid new positions, and recent high-volume drop without flagged reversal signals. The EMA and SMA have been tightly intertwined over the past month, with their difference often less than typical daily price ranges (e.g., 0.12 vs. 0.28 on the latest bar), and they've crossed at least once recently around 9/8, while price has fluctuated around them without clear directionâ€”qualifying the trend as unclear and warranting no new entries. MACD remains negative at -0.1984 with a bearish histogram, RSI at 43.9 suggests neither extreme, and there's no flagged volume capitulation ("!" or "BOT") in the past month to justify buying a dip in this downtrend. Support levels are noted at $23.76 (strength 2, last tested 28 bars ago) and $22.81 (67 bars ago), but the stock is trading above them without testing, while resistance at $25.12 was just bounced off 0 bars ago, reinforcing a ranging but downward-biased pattern....
2025-09-16	CASH
Summary: Staying in cash as PFE is in a downtrend with no volume capitulation, preventing long entry, and shorting pharmaceuticals is avoided due to high risk of sudden positive news spikes....
2025-09-15	CASH
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly rangebound without volume capitulation, price below both indicating downtrend, and no high-confidence setup for entry given pharmaceutical stock risks and recent trade losses....
2025-09-12	CASH
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly rangebound and recently crossing, price below both without volume capitulation, avoiding new entries per technical priority despite support at $23.91 and high volume today potentially signaling a bottom....
2025-09-11	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA, price slightly above both in a tight range without volume capitulation, recent trade history of losses on longs from similar choppy action, and no high-confidence setup for entry despite neutral RSI and minor support nearby. MACD shows a bearish stance at -0.0123 below its signal line at 0.0406, and RSI at 50.7 is neutral, not indicating oversold conditions for a reversal. Volume on 9/11 was moderate at 28.9M, below recent averages, suggesting lack of conviction....
2025-09-10	CASH
Summary: Staying in cash as the trend is unclear with tightly rangebound EMA and SMA, price below both in a potential downtrend without volume capitulation, and recent long trades ended in losses due to bearish technicals like price falling below MAs and negative MACD crossovers....
2025-09-09	CASH
Summary: Staying in cash as the chart shows a downtrend with price below both EMA and SMA, no recent volume capitulation to justify a long entry, and shorting pharmaceuticals is avoided due to high risk of sudden positive news spikes....
2025-09-08	CASH
Summary: Staying in cash for PFE as the chart shows a downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, shorting prohibited for pharma stocks, and recent trade history indicates caution after quick losses on longs. Over the past month, the EMA and SMA have been tightly rangebound with minimal separation (often less than 0.1, smaller than typical daily ranges of 0.3-0.6), and they've crossed at least twice (e.g., around 8/28 and 9/2), while price has fluctuated around them without clear direction, making the trend unclear and advising against new entries. MACD is slightly positive at 0.0051 but below its signal line at 0.0884, suggesting weakening momentum, and RSI at 45 is neutral but not oversold. Volume on this down day was moderate at 40M, not indicating capitulation, and there's no flagged "!" or "BOT" in the past month to justify buying in this downtrend....
2025-09-05	CASH
Summary: Staying in cash due to unclear trend with EMA and SMA tightly rangebound and price fluctuating around them without clear direction, no volume capitulation, and recent losing trades in similar setups....
2025-09-04	CASH
Summary: Staying in cash due to unclear trend with EMA and SMA tightly rangebound without clear direction, price below both, no volume capitulation, and recent exit on 8/28/2025 at similar levels without significant new positive catalysts to justify quick re-entry. This setup advises against new entries, especially following the recent long exit on 8/28/2025 at 24.60 due to bearish MACD crossover and pullback; re-entering now would require a better price or major shift, but current levels are comparable without such justification....
2025-09-03	CASH
Summary: Trend remains unclear with price below both EMA and SMA, bearish MACD crossover, no volume capitulation, and recent exit from long on 8/28/2025 without compelling new reasons for quick re-entry like a strong catalyst or better price....
2025-09-02	CASH
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly rangebound without clear separation or volume capitulation, price sitting between them after recent exits at losses, and no high-confidence setup for entry given Pfizer's pharma volatility and lack of immediate catalysts....
2025-08-29	CASH
Summary: Staying in cash as the trend is unclear with price below both EMA and SMA despite EMA above SMA, no volume capitulation for a long entry in this setup, and we just exited a long position yesterday at a lower price without new compelling information justifying quick re-entry....
2025-08-28	SOLD
Summary: Exiting the long position in PFE as price has fallen below both EMA and SMA, MACD shows bearish crossover, and no volume capitulation supports a reversal, with recent pullback testing support at $23.76 amid neutral news flow....
2025-08-27	HOLD LONG
Summary: Holding the long position in PFE as the uptrend continues with price above EMA and SMA, positive MACD, no breakdown below key supports like $23.76, and approaching resistance at $26.52 without reversal signals, supported by recent positive news on drug developments....
2025-08-26	HOLD LONG
Summary: Holding the long position in PFE as the uptrend persists with price above both EMA and SMA, positive MACD momentum, no breakdowns below supports like $23.76, and still approaching resistance at $26.52 without clear reversal signals....
2025-08-25	HOLD LONG
Summary: Holding the long position in PFE as the uptrend continues with price above EMA and SMA, positive MACD, no breakdowns below key supports like $23.76, and approaching resistance at $26.52 without signs of reversal....
2025-08-22	HOLD LONG
Summary: Holding the long position in PFE as the uptrend persists with price above EMA and SMA, positive MACD, no breakdowns below supports like $23.76, and resistance at $26.52 approaching but not yet tested....
2025-08-21	HOLD LONG
Summary: Holding the long position in PFE as the uptrend continues with price above EMA and SMA, positive MACD, no breakdowns below key supports like $23.76, and resistance at $26.52 not yet tested....
2025-08-20	HOLD LONG
Summary: Holding the long position in PFE as the uptrend persists with price above EMA and SMA, positive MACD divergence, no breakdowns below supports like $23.76, and no imminent catalysts or resistance at $26.52 reached yet....
2025-08-19	HOLD LONG
Summary: Holding the long position as PFE remains in an uptrend with price above EMA and SMA, positive MACD, no breakdowns below key supports like $23.76, and no imminent catalysts or resistance breaches at $26.52 signaling an exit....
2025-08-18	HOLD LONG
Summary: Holding the long position as the price remains above both EMA and SMA with positive MACD momentum, no breakdowns below support, and no imminent catalysts or resistance breaches signaling an exit. MACD is positive at 0.1265 above its signal line at 0.0164, supporting continued momentum, and RSI at 56.39 is neutral without overbought conditions. Volume on 8/18 was moderate at 25.58M, not indicating capitulation or exhaustion....
2025-08-15	HOLD LONG
Summary: Continuing to hold the long position as the uptrend persists with price above EMA and SMA, positive MACD, and no breakdowns or catalysts signaling an exit, while nearing but not yet breaking resistance at $25.42....
2025-08-14	HOLD LONG
Summary: Continue holding the existing long position as price holds above EMA and SMA in a post-earnings recovery, nearing resistance at $25.42 with positive MACD crossover and no immediate catalysts or breakdowns signaling an exit. Volume on the latest bar was moderate at 23 million shares, and RSI at 57.91 suggests room for upside without being overbought. MACD has turned positive (0.067 vs. signal -0.039), supporting momentum, while the stock respects rising support around $24.86 from recent trendlines....
2025-08-13	HOLD LONG
Summary: Continue holding the existing long position as price remains above EMA and SMA in a post-earnings uptrend, approaching resistance at $25.42 without breakdown or near-term catalysts....
2025-08-12	HOLD LONG
Summary: Continue holding the existing long position as the chart shows price still above both EMA and SMA post-earnings recovery, targeting resistance at $25.42 without clear trend breakdown or immediate catalysts. ...
2025-08-11	HOLD LONG
Summary: Hold the existing long position as the chart shows price recovering above EMA and SMA after post-earnings dip, targeting resistance at $25.42 with no immediate catalysts or trend breakdown justifying early exit....
2025-08-08	HOLD LONG
Summary: Hold the long position as Pfizer's chart shows recovery with price above tightly bound EMA and SMA post-Q2 earnings beat and raised EPS guidance, targeting resistance at $25.42 for multi-week gains without immediate catalysts....
2025-08-07	HOLD LONG
Summary: Pfizer's chart shows an unclear trend with EMA and SMA tightly bound and price below both after a post-earnings dip, but strong Q2 results, raised EPS guidance, and no immediate catalysts support holding the long position entered at $24.75 for a potential multi-week recovery....
2025-08-06	HOLD LONG
Summary: Pfizer's post-earnings pullback shows price dipping below EMA and SMA amid unclear trend from frequent crossings, but positive fundamentals like raised EPS guidance and no upcoming catalysts support holding the long position for potential multi-week recovery without violating technical rules. Fundamentals are strongâ€”recent news from sources like BioSpace and CNBC highlights Pfizer's Q2 2025 results with 10% revenue growth, raised full-year EPS guidance to $2.90-$3.10, and cost cuts underway, which could fuel upward momentum. Sentiment on X is positive, with posts noting the profit outlook hike and strong performance, aligning with the pharma sector's potential for quick rebounds on good news....
2025-08-05	BUY
Summary: Pfizer's chart shows a clear uptrend with price above both EMA and SMA after a strong earnings beat and raised guidance, signaling upward momentum for a multi-week hold despite recent exit at a loss....
2025-08-04	CASH
Summary: Upcoming earnings on August 5, 2025, pose significant volatility risk without solid technical support for entry, while the chart shows an unclear trend with price below both EMA and SMA, advising patience after recent long position loss....
2025-08-01	SOLD
Summary: Exiting the long position due to unclear trend with price below both EMA and SMA, recent downward momentum, and upcoming Q2 earnings on August 5, 2025, introducing volatility risk without solid technical support for holding through....
2025-07-31	HOLD LONG
Summary: Holding the long position as Pfizer's stock is approaching key support amid positive oncology pipeline sentiment and upcoming earnings on August 5, 2025, with technicals showing potential for rebound without immediate earnings risk....
2025-07-30	HOLD LONG
Summary: Continuing to hold long position as Pfizer's stock shows resilience near rising support levels amid recovery from April lows and positive oncology pipeline developments, with earnings on August 5, 2025 approaching but not yet within the critical window....
2025-07-29	HOLD LONG
Summary: Holding long as Pfizer's recovery from April lows continues with recent licensing agreement boosting oncology pipeline, despite unclear trend, ahead of earnings on August 5, 2025....
2025-07-28	HOLD LONG
Summary: Pfizer's stock is holding above rising support with positive MACD crossover and recent EMA approval for a new COVID-19 vaccine, supporting continued upward momentum despite a minor pullback, with Q2 earnings on August 5 providing a potential catalyst....
2025-07-25	HOLD LONG
Summary: Hold long position as recovery trend from April lows remains intact with positive MACD, supportive news on cost savings and oncology, despite upcoming earnings on Aug 5 which could act as catalyst....
2025-07-24	HOLD LONG
Summary: Pfizer's uptrend remains intact with EMA above SMA and price above both, supported by positive news on oncology pivot and analyst holds, indicating continued upward momentum without near-term catalysts to exit....
2025-07-23	HOLD LONG
Summary: Pfizer's uptrend persists with price above rising EMA and SMA, positive MACD, recent gains, and upbeat sentiment from insider buying and analyst targets outweighing stagnant concerns ahead of Q2 earnings on August 5, 2025. ...
2025-07-22	HOLD LONG
Summary: Continuing long position in PFE due to sustained uptrend with EMA above SMA and price above both, positive MACD crossover, holding above rising support from April lows, supported by recent positive hemophilia drug trial results, insider buying over $32M this year, and bullish analyst ratings (18/24 buy) ahead of July 29 earnings, indicating potential for multi-week gains....
2025-07-21	HOLD LONG
Summary: Pfizer's chart indicates a continuing recovery from April lows with EMA above SMA, price holding above key support, and recent positive news on drug approvals supporting multi-week upward momentum despite short-term pullback. The chart shows price dipping today but respecting the rising support trendline around $23.94 (with slope 0.0437 and recent bounces), and no volume capitulation flagged (no "!" or "BOT" in data), suggesting the pullback could be a dip in an uptrend rather than reversal. MACD is positive at 0.1587 but below signal (0.3153), hinting at weakening momentum, yet it's still above zero, aligning with the prior recovery rationale....
2025-07-18	BUY
Summary: Pfizer's chart shows a strong recovery from April lows with positive MACD and holding above rising support, supported by recent positive drug trial news indicating upward momentum for a multi-week hold....